Preparation and Characterization of DHAD/HRP 2 Co-loaded Multivesicular Liposomes

The structure of carriers play an important role in the space distribution of difierent drugs, therefore this paper studies multivesicular liposomes (MVLs), which have a unique nano-in-micro structure as possible carriers in combination therapy. Horseradish peroxidase (HRP) and mitoxantrone hydrochloride (DHAD) were selected as model drugs for protein and small molecule drug respectively. The results show that the MVLs are spherical and that the internal space is divided up into numerous compartments. The particle size ranged from 15 to 20 „m and the system was stable according to the zeta potentials. In vitro release studies display that the DHAD/HRP co-loaded MVLs has better sustained release proflles than one drug alone, and the MVLs exhibited an orderly release behavior which suggested that MVLs might be used as drug carriers in combination therapy applications.

[1]  James Brian Byrd,et al.  Combination therapy as initial treatment for newly diagnosed hypertension. , 2011, American heart journal.

[2]  T. Kondo,et al.  Effects of preparation conditions on the monodispersity of albumin microspheres. , 1998, Journal of microencapsulation.

[3]  Zheng Huang,et al.  Combination of immunotherapy and photodynamic therapy in the treatment of Bowenoid papulosis. , 2007, Photodiagnosis and photodynamic therapy.

[4]  Aizheng Chen,et al.  Preparation of embolic NEMs loading capecitabine , 2012, Journal of Materials Science: Materials in Medicine.

[5]  S. Mantripragada.  A lipid based depot (DepoFoam technology) for sustained release drug delivery. , 2002, Progress in lipid research.

[6]  J. Sosman,et al.  Combination targeted therapy in advanced renal cell carcinoma , 2009, Cancer.

[7]  S. Ross,et al.  Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. , 2013, Diabetes & metabolism.

[8]  Ying-jie Deng,et al.  Multivesicular liposome formulation for the sustained delivery of breviscapine. , 2005, International journal of pharmaceutics.

[9]  S. Kaplan,et al.  Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. , 2013, European urology.

[10]  T. Kararli,et al.  Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[11]  J. Hooker,et al.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. , 2013, Cancer letters.

[12]  Athanasios Mantalaris,et al.  Simulation of ex vivo bone marrow culture: Application to chronic myeloid leukaemia growth model , 2012 .

[13]  J. Woodcock,et al.  Development of novel combination therapies. , 2011, The New England journal of medicine.

[14]  María J. Vicent,et al.  Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.

[15]  Jian-Mei Xu,et al.  The Preparation of Silk Fibroin Drug-loading Microspheres , 2008 .

[16]  J. Moalem,et al.  Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma. , 2012, Surgery.

[17]  K. Ulbrich,et al.  Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Rebecca Slack,et al.  A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy , 2012, Cancer Chemotherapy and Pharmacology.

[19]  Liangfang Zhang,et al.  Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. , 2012, Biochemical pharmacology.

[20]  M. Buti,et al.  Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. , 2012, Journal of hepatology.

[21]  M. Hughes,et al.  Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. , 2002, International journal of pharmaceutics.

[22]  Liu Yuan.  Preparation and Characterization of a Novel Embolic Nano-in-Micro Drug Delivery System , 2011 .

[23]  Aizheng Chen,et al.  Preparation of nanoparticles embedded microcapsules (NEMs) and their application in drug release , 2012 .

[24]  Q. Ye,et al.  DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. , 2000, Journal of controlled release : official journal of the Controlled Release Society.